Drug Patents Expiring in 2040
1. Agamree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11382922 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Jul, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11471471 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Treatment: Treatment of duchenne muscular dystrophy
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
2. Airduo Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11969544 (Pediatric) | TEVA PHARM | Inhalers and airflow adaptors therefor |
Feb, 2040
(15 years from now) | |
|
US11344685 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2040
(15 years from now) | |
| US11439777 | TEVA PHARM | Drug delivery device with electronics |
May, 2040
(15 years from now) | |
| US11464923 | TEVA PHARM | Inhaler system |
Jun, 2040
(15 years from now) | |
| US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
3. Airduo Respiclick patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11969544 (Pediatric) | TEVA PHARM | Inhalers and airflow adaptors therefor |
Feb, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
4. Ameluz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 10, 2019 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminat...
Dosage: GEL
More Information on Dosage
AMELUZ family patents
5. Armonair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11969544 (Pediatric) | TEVA PHARM | Inhalers and airflow adaptors therefor |
Feb, 2040
(15 years from now) | |
|
US11344685 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2040
(15 years from now) | |
| US11439777 | TEVA PHARM | Drug delivery device with electronics |
May, 2040
(15 years from now) | |
| US11464923 | TEVA PHARM | Inhaler system |
Jun, 2040
(15 years from now) | |
| US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(15 years from now) | |
|
US11439777 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Nov, 2040
(15 years from now) | |
|
US11464923 (Pediatric) | TEVA PHARM | Inhaler system |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
6. Armonair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11969544 (Pediatric) | TEVA PHARM | Inhalers and airflow adaptors therefor |
Feb, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR RESPICLICK family patents
7. Auvelity patent expiration
AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10780064 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(15 years from now) | |
| US10925842 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(15 years from now) | |
| US10940124 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(15 years from now) | |
| US10966942 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage
AUVELITY family patents
8. Ayvakit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11964980 | BLUEPRINT MEDICINES | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
Apr, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11999744 | BLUEPRINT MEDICINES | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
Apr, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-863) | Jun 16, 2024 |
| New Indication(I-864) | Jun 16, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 09, 2025 |
| New Indication(I-912) | May 22, 2026 |
| Orphan Drug Exclusivity(ODE-366) | Jan 09, 2027 |
| Orphan Drug Exclusivity(ODE-356) | Jun 16, 2028 |
| Orphan Drug Exclusivity(ODE-434) | May 22, 2030 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 10 January, 2024
Market Authorisation Date: 16 June, 2021
Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...
Dosage: TABLET
More Information on Dosage
AYVAKIT family patents
9. Bynfezia Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11246991 | SUN PHARM | Electrolysis-resistant coupling assembly for valves |
Nov, 2040
(15 years from now) | |
| US11534553 | SUN PHARM | Method of injecting octreotide acetate into the body |
Nov, 2040
(15 years from now) | |
| US11052196 | SUN PHARM | Method of injecting octreotide acetate into the body |
Nov, 2040
(15 years from now) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 27 September, 2024
Treatment: Method of treating severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
Dosage: SOLUTION
More Information on Dosage
BYNFEZIA PEN family patents
10. Cabtreo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389467 | BAUSCH | Topical compositions |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2026 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2023
Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older
Dosage: GEL
More Information on Dosage
CABTREO family patents
11. Caplyta patent expiration
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12090155 | INTRA-CELLULAR | Methods |
Jul, 2040
(15 years from now) | |
| US11753419 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(15 years from now) | |
| US12122792 | INTRA-CELLULAR | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of depressive episodes or major depressive episodes associated with bipolar ii disorder; Treatment of schizophrenia by inhibiting the 5-ht2a receptor, inhibiting the serotonin transporter, a...
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
12. Carnexiv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11529357 | LUNDBECK PHARMS LLC | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
CARNEXIV family patents
13. Daybue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11370755 | ACADIA PHARMS INC | Compositions of trofinetide |
Aug, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
14. Elucirem patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590246 | GUERBET | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ELUCIREM family patents
15. Emerphed patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11464752 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | |
| US11241400 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | |
| US11571398 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | |
| US11478436 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | |
| US11090278 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 28 February, 2023
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION
How can I launch a generic of EMERPHED before it's drug patent expiration?
More Information on Dosage
EMERPHED family patents
16. Ephedrine Sulfate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12029710 | ENDO OPERATIONS | Ephedrine compositions and methods |
Jan, 2040
(15 years from now) | |
| US10869845 | ENDO OPERATIONS | Ephedrine compositions and methods |
Jan, 2040
(15 years from now) | |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of clinically important hypotension occurring in the setting of anesthesia
Dosage: SOLUTION
How can I launch a generic of EPHEDRINE SULFATE before it's drug patent expiration?
More Information on Dosage
EPHEDRINE SULFATE family patents
17. Eprontia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11911362 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(15 years from now) | |
| US11633374 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(15 years from now) | |
| US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(15 years from now) | |
| US11826343 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(15 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 05 November, 2021
Treatment: Indicated for the preventive treatment of migraine in patients 12 years and older
Dosage: SOLUTION
How can I launch a generic of EPRONTIA before it's drug patent expiration?
More Information on Dosage
EPRONTIA family patents
18. Epsolay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11865100 | GALDERMA LABS LP | Method for treatment of rosacea in patients aged 65 years and older |
Feb, 2040
(15 years from now) | |
| US10933046 | GALDERMA LABS LP | Method for treatment of rosacea in patients aged 65 years and older |
Feb, 2040
(15 years from now) | |
| US11986456 | GALDERMA LABS LP | Method for treatment of rosacea |
Feb, 2040
(15 years from now) | |
| US11877997 | GALDERMA LABS LP | Method for providing early onset of action in the treatment of rosacea |
Feb, 2040
(15 years from now) | |
| US10945987 | GALDERMA LABS LP | Method for providing early onset of action in the treatment of rosacea |
Feb, 2040
(15 years from now) | |
| US11541026 | GALDERMA LABS LP | Method for treatment of rosacea |
Feb, 2040
(15 years from now) | |
| US11426378 | GALDERMA LABS LP | Method for long-term treatment of rosacea |
Aug, 2040
(15 years from now) | |
| US11628155 | GALDERMA LABS LP | Method for therapeutic treatment of rosacea |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older; Topical treatment of rosacea; Topical treatment of inflammatory lesions of rosacea in adults 18 years of age a...
Dosage: CREAM
More Information on Dosage
EPSOLAY family patents
19. Erleada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11963952 | JANSSEN BIOTECH | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment of metastatic castration sensitive prostate cancer
Dosage: TABLET
How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage
ERLEADA family patents
20. Farxiga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11826376 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jan, 2040
(15 years from now) | |
| US11903955 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(15 years from now) | |
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(15 years from now) | |
|
US10973836 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Sep, 2040
(15 years from now) | |
|
US11903955 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Sep, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure with reduced ejection fraction, without type ii diabetes, and having an hba1c of < 5.7%; Reduction of t...
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
21. Fyarro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497737 | AADI | Pharmaceutical compositions of albumin and rapamycin |
Oct, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 22, 2024 |
| Orphan Drug Exclusivity(ODE-386) | Nov 22, 2028 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: NA
Dosage: POWDER
More Information on Dosage
FYARRO family patents
22. Gemtesa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12102638 | UROVANT | Use of vibegron to treat overactive bladder |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
23. Genosyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11672938 | VERO BIOTECH INC | Start-up protocols for nitric oxide delivery device |
Jul, 2040
(15 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method of delivering nitric oxide to a patient
Dosage: GAS
More Information on Dosage
GENOSYL family patents
24. Hetlioz Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11202770 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
HETLIOZ LQ family patents
25. Igalmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12109196 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jul, 2040
(15 years from now) | |
| US11890272 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jul, 2040
(15 years from now) | |
| US11998529 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jul, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration; Acute treatment of agitation associated with bipolar i or ii disorder by ...
Dosage: FILM
More Information on Dosage
IGALMI family patents
26. Ingrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
| New Indication(I-925) | Aug 18, 2026 |
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE
How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage
INGREZZA family patents
27. Ingrezza Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-925) | Aug 18, 2026 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Market Authorisation Date: 30 April, 2024
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE
More Information on Dosage
INGREZZA SPRINKLE family patents
28. Konvomep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11771686 | AZURITY | Compositions and kits for omeprazole suspension |
Mar, 2040
(15 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: Short term treatment of active benign gastric ulcer
Dosage: FOR SUSPENSION
More Information on Dosage
KONVOMEP family patents
29. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11879013 | JANSSEN BIOTECH | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
May, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, in combination with amivantam...
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
30. Liletta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571328 | MEDICINES360 | IUD insertion devices |
Sep, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 26, 2018 |
| New Indication(I-917) | Jun 29, 2026 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
LILETTA family patents
31. Livmarli patent expiration
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| US11918578 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| ODE*(ODE*) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients 3 months of age and older with alagille syndrome (algs)
Dosage: SOLUTION
More Information on Dosage
LIVMARLI family patents
32. Lumakras patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11827635 | AMGEN INC | Solid state forms |
May, 2040
(15 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Sep, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| ODE*(ODE*) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-352) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET
More Information on Dosage
LUMAKRAS family patents
33. Lumryz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10925844 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Feb, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 01, 2026 |
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| Orphan Drug Exclusivity(ODE-494) | Oct 16, 2031 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
LUMRYZ family patents
34. Motpoly Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337943 | AUCTA | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(15 years from now) | |
| US11883374 | AUCTA | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(15 years from now) | |
| US12042474 | AUCTA | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(15 years from now) | |
Drugs and Companies using LACOSAMIDE ingredient
Market Authorisation Date: 04 May, 2023
Treatment: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg; Treatment of partial-onset seizures in adults and in pedia...
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
MOTPOLY XR family patents
35. Mycapssa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141457 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(16 years from now) | |
| US11890316 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
| Orphan Drug Exclusivity(ODE-474) | Jun 26, 2027 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
MYCAPSSA family patents
36. Nexletol patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11760714 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(15 years from now) | |
| US11926584 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
| New Indication(I-943) | Mar 22, 2027 |
| New Indication(I-944) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 21 February, 2020
Treatment: A method of lowering low-density lipoprotein cholesterol (ldl-c) in a human patient in need thereof comprising administration of bempedoic acid alone or in combination with other lipid lowering therap...
Dosage: TABLET
More Information on Dosage
NEXLETOL family patents
37. Nexlizet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11926584 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(15 years from now) | |
| US11760714 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 26, 2023 |
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
| New Indication(I-943) | Mar 22, 2027 |
| New Indication(I-945) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: A method of lowering low-density lipoprotein cholesterol (ldl-c) in a human patient in need thereof comprising administration of bempedoic acid alone or in combination with other lipid lowering therap...
Dosage: TABLET
More Information on Dosage
NEXLIZET family patents
38. Ojjaara patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11963962 | GLAXOSMITHKLINE | Platelet count-agnostic methods of treating myelofibrosis |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis in subjects having a baseline platelet count of less than 50 billion/l
Dosage: TABLET
More Information on Dosage
OJJAARA family patents
39. Opzelura patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590138 | INCYTE CORP | Topical treatment of vitiligo by a jak inhibitor |
Jun, 2040
(15 years from now) | |
| US11510923 | INCYTE CORP | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
Sep, 2040
(15 years from now) | |
| US11590137 | INCYTE CORP | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
Sep, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: For the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of phototherapy, wherein the vitiligo affects at least one of the lower ext...
Dosage: CREAM
More Information on Dosage
OPZELURA family patents
40. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while co-administering omeprazole
Dosage: CAPSULE
How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
41. Orilissa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg or 200 mg elagolix while co-administering omeprazole
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents
42. Pemazyre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11628162 | INCYTE CORP | Methods of treating cancer with an FGFR inhibitor |
Aug, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-899) | Aug 26, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of relapsed or refractory myeloid/lymphoid neoplasms with fgfr1 rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inhibitors
Dosage: TABLET
More Information on Dosage
PEMAZYRE family patents
43. Proair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439777 | TEVA BRANDED PHARM | Drug delivery device with electronics |
May, 2040
(15 years from now) | |
| US11464923 | TEVA BRANDED PHARM | Inhaler system |
Jun, 2040
(15 years from now) | |
| US11173259 | TEVA BRANDED PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(15 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR DIGIHALER family patents
44. Qdolo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103452 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(15 years from now) | |
| US11752103 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(15 years from now) | |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION
More Information on Dosage
QDOLO family patents
45. Qinlock patent expiration
Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12023325 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US12059411 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US12059410 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11813251 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11576904 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11529336 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11534432 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US12023327 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US12023326 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | |
| US11793795 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11850240 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11911370 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11576903 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11801237 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11896585 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11850241 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US12023328 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11969415 | DECIPHERA PHARMS | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11903933 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11844788 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US12064422 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11612591 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11918564 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of advanced gastrointestinal stromal tumor in patients previously administered imatinib; Treatment of gastrointestinal stromal tumors in patients suffering from palmar-plantar erythrodysesth...
Dosage: TABLET
More Information on Dosage
QINLOCK family patents
46. Recorlev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11903940 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(15 years from now) | |
| US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(15 years from now) | |
| US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-385) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use an oct2 substrate, monitoring the subject for a dose limiting event and adjusting the...
Dosage: TABLET
More Information on Dosage
RECORLEV family patents
47. Relyvrio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583542 | AMYLYX | Compositions of bile acids and phenylbutyrate compounds |
Jul, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2027 |
| Orphan Drug Exclusivity(ODE-411) | Sep 29, 2029 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 29 September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
RELYVRIO family patents
48. Reyvow patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12071423 | ELI LILLY AND CO | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate |
Jul, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
REYVOW family patents
49. Scemblix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| ODE*(ODE*) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
SCEMBLIX family patents
50. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11566000 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(15 years from now) | |
| US11584715 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: NA
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
51. Spravato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11883526 | JANSSEN PHARMS | Esketamine for the treatment of depression |
Feb, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-840) | Jul 31, 2023 |
| NCE*(NCE*) | Mar 05, 2024 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of trd with nasally administered esketamine in conjunction with an oad in a patient who has missed a dose during the maintenance phase and had worsening of depression symptom by returning to...
Dosage: SPRAY
More Information on Dosage
SPRAVATO family patents
52. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11969404 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having no, mild, moderate, or severe renal impairment; Treatment of excessive daytime sleepiness by administering s...
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
53. Sympazan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541002 | OTTER PHARMS | Oral film compositions and dosage forms having precise active dissolution profiles |
Jan, 2040
(15 years from now) | |
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: Method of treating seizures
Dosage: FILM
More Information on Dosage
SYMPAZAN family patents
54. Tlando patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12011503 | VERITY | Fixed dose oral testosterone undecanoate compositions and use thereof |
Oct, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Methods of continuing or discontinuing a dosage regimen of a testosterone undecanoate pharmaceutical composition to a hypogonadal male subject
Dosage: CAPSULE
More Information on Dosage
TLANDO family patents
55. Tymlos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11255842 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(15 years from now) | |
| US11680942 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Use for detecting neutralizing antibodies
Dosage: SOLUTION
How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage
TYMLOS family patents
List of large molecules
1. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11555176 | REGENERON PHARMACEUTICALS, INC. | Cell culture medium for eukaryotic cells |
Jan, 2040
(15 years from now) | |
| US11439758 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for precision dose delivery |
Jun, 2040
(15 years from now) | |
| US11478588 | REGENERON PHARMACEUTICALS, INC. | Needle shield grip devices and related methods |
Jul, 2040
(15 years from now) | |
| US11793926 | REGENERON PHARMACEUTICALS, INC. | Medical device packaging and related methods |
Jul, 2040
(15 years from now) | |
| US11299532 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11306135 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11459374 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11459373 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11472861 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(15 years from now) | |
| US11485770 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11505593 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11548932 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11753459 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11104715 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(15 years from now) | |
| US11174283 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11186625 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11053280 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11542317 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11535663 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(15 years from now) | |
| US11732025 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(15 years from now) | |
| US11525833 | REGENERON PHARMACEUTICALS, INC. | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis |
Nov, 2040
(15 years from now) |
Ingredients: AFLIBERCEPT